CMS Open Payments · Program Year 2024
Occlutech US LLC
Occlutech US LLC reported $1,155,855.11 across General Payments, Research, and Ownership to 120 physicians and teaching hospitals across 120 transactions.
- $1.2M Above-median payer
- All-tracks total
- 120 Below-median volume
- Transactions
- 120 Below-median reach
- Recipients
- #588
- of 1,925 companies
Occlutech US LLC reported $1,155,855.11 across all CMS Open Payments tracks (General + Research + Ownership) to 120 physicians and teaching hospitals in Program Year 2024 - ranking #588 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $1,155,855.11, averaging $9.6K per recipient.
Occlutech US LLC's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
13/100
Total payments
F
21/100
Transaction volume
F
11/100
Physician reach
F
11/100
Payment type diversity
F
10/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer occlutech-us-llc Occlutech US LLC
$1.2M · #588/1,925 · 0.0% industry · PY2024
- TOT $1.2M
- RANK #588
- SHARE 0.0%
- TXN 120
- RCP 120
- CAT 1
- GEN $1.2M
- TOP1 25.4%
- PY 2024
Volume peers
Nearest volume peer: Noah Medical Corporation ($1.2M)
Occlutech US LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for Occlutech US LLC
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Occlutech US LLC that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
Of the 1 general-payment categories charted below, "Grant" is the largest at $1.2M across 120 transactions, 100.0% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 1 types of general payments, Occlutech US LLC's largest category was "Grant" at $1.2M - 100.0% of General Payments.
How Occlutech US LLC divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Grant | $1.2M | 120 | 100.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $584,146.58 (50.5%) of $1,155,855.11 in this company's General Payments records across 29 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Occlutech US LLC
The five named recipients with the highest reported General Payments from this company
- 1
Baystate Medical Center
$293,981.60 across 5 reported transactions
- 2
Tufts Medical Center
$80,347.50 across 8 reported transactions
- 3
Massachusetts General Hospital
$78,726.00 across 9 reported transactions
- 4
The Nebraska Medical Center
$76,262.48 across 6 reported transactions
- 5
Osf Heart Of Mary Medical Center
$54,829.00 across 6 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Occlutech US LLC ranks #588 of 1,925 by total payments (top 31% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,045 of 1,838 by HHI (bottom 43% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- OssDsign Incorporated : $88.5K total payments, HHI 981
- Mf Med : $630.54 total payments, HHI 979
- B. Braun Medical Inc. : $221.2K total payments, HHI 975
- Vioptix Inc : $4.7K total payments, HHI 971
- Bolton Medical Inc : $2.2M total payments, HHI 970
- Ge Healthcare : $6.4M total payments, HHI 966
- Occlutech US LLC (this company) : $1.2M total payments, HHI 961
- Cytyc Surgical Products, LLC : $12.4K total payments, HHI 961
- BioXcel Therapeutics, Inc. : $116.0K total payments, HHI 958
- Spinefrontier, Inc. : $26.7K total payments, HHI 958
- PARI Respiratory Equipment, Inc. : $262.70 total payments, HHI 954
- Rayner Intraocular Lenses Limited : $262.7K total payments, HHI 950
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Occlutech US LLC's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Occlutech US LLC.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Occlutech US LLC.
Showing 6 of 1,924 companies with CMS-reported payment data.
Revance Therapeutics, Inc.
New Wave Endo-Surgical Corp.
Ossio Ltd
Gynesonics, Inc.
Fisher & Paykel Healthcare Limited
Put this to use
Occlutech US LLC ranks #588 of 1,925 by all-tracks total payments, led by "Grant".
- See where Occlutech US LLC sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Grant" spend across every manufacturer, not just Occlutech US LLC. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.